Sudeep Pharma FY26: Revenue up 28%, PAT at ₹174 cr
Speciality ingredients segment drives strong performance; company recommends ₹1.50 per share final dividend.
— 1 earlier story on Sudeep Pharma Ltd. →Mkt cap₹7,605 cr
P/E70.70×
ROE28.13%
Debt / eq.0.27
₹174 cr FY26 consolidated PAT, up 26% YoY
What's new with Sudeep Pharma Ltd.
- Revenue up 28% YoY to ₹642 cr; PAT up 26% to ₹174 cr.
- Board recommends final dividend of ₹1.50 per share.
- Strong show from speciality ingredients and NSS Ireland acquisition.
Why this matters for Sudeep Pharma Ltd.
The growth is solid, but largely anticipated from prior quarterly updates. The dividend signals management confidence in cash flows.
What we're watching
- Q1 FY27 performance in speciality ingredients.
- Further margin trends amid input cost volatility.
- Integration benefits from NSS Ireland.
The full read
Sudeep Pharma closed FY26 with consolidated revenue of ₹642 crore, up 28% year-on-year, and PAT of ₹174 crore, up 26%. The speciality ingredients segment and the NSS Ireland acquisition drove the growth. The board recommended a final dividend of ₹1.50 per share. While the numbers are strong, they were largely in line with market expectations built from quarterly updates. The focus now shifts to sustaining momentum in FY27 and realising further synergies from the recent acquisition.
Mentioned: NSS Ireland · ₹1.50 dividend